Answers are grounded in this paper and cite their sources.
Crohn's disease is a chronic gastrointestinal inflammatory disorder, characterized by episodes of relapsing and remitting flares. As the disease mechanism becomes better elucidated, there is a significant increase in the number of available biologic therapies. This article summarizes and synthesizes current Food and Drug Administration-approved biological therapy for Crohn's disease and examines the positioning of medical therapy as emerging biologics break onto the market.
No takes yet. Share an insight, caveat, or question.
Dunleavy et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: